CVS resumes coverage of blockbuster blood thinner after price drop follows January exclusion

Zachary Brennan

Senior Editor

Following some backlash from the American College of Cardiology and patients, Bristol Myers Squibb and Pfizer lowered the price of their blockbuster blood thinner Eliquis …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

CVS resumes coverage of blockbuster blood thinner after price drop follows January exclusion

Zachary Brennan

Senior Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Is there still hope for Summit's cancer drug buried in the data?

MIT scientists’ AI model one-ups AlphaFold 3, takes on ‘fundamental issue’ in drug R&D

EMA considers serious eye condition a ‘very rare’ side effect of semaglutide

Regeneron makes $80M obesity deal with Hansoh

At a crossroads, biotechs are passing on reverse mergers in 2025

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...

CVS re­sumes cov­er­age of block­buster blood thin­ner af­ter price drop fol­lows Jan­u­ary ex­clu­sion

Senior Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

CVS resumes coverage of blockbuster blood thinner after price drop follows January exclusion